| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $2,278,582 ) |
| | 2025 | 2025 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AI174357 | Development of ultra-efficient antibodies for single cell mapping applications | 000 | 3 | NIH | 2/12/2025 | $1,004,302 |
| | 2025 | 2025 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM153000 | Biochemical and genomic tools to study histone ADP ribosylation signaling | 000 | 2 | NIH | 4/2/2025 | $1,274,280 |
| | 2025 | 2023 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43CA284973 | Epigenomic analysis of cell-free nucleosomes for cancer research | 000 | 1 | NIH | 10/18/2024 | $0 |
| | 2025 | 2023 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43HG013071 | Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | 000 | 1 | NIH | 2/13/2025 | $0 |
| | 2025 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG010595 | Quantitative mapping of combinatorial histone modifications | 000 | 3 | NIH | 2/6/2025 | $0 |
| | 2025 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DA057749 | A novel platform for quantification of acute neuronal transcriptional responses | 000 | 1 | NIH | 2/5/2025 | $0 |
| | 2025 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43AG076049 | High-resolution genomic mapping of ssDNA and associated proteins for Alzheimer's disease research | 000 | 1 | NIH | 12/19/2024 | $0 |
| | 2025 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG010640 | Development of efficient quantitative chromatin profiling in kit and high-throughput formats | 000 | 3 | NIH | 2/19/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $11,622,850 ) |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 000 | 3 | NIH | 1/5/2024 | $1,032,776 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AG087752 | Versatile genomics platform for unbiased analysis of chromatin-associated RNAs and nascent transcripts | 000 | 1 | NIH | 8/12/2024 | $1,274,993 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM149036 | Novel recombinant sensors to study histone ubiquitin signaling | 000 | 2 | NIH | 5/20/2024 | $1,273,178 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM153000 | Biochemical and genomic tools to study histone ADP ribosylation signaling | 000 | 1 | NIH | 2/6/2024 | $1,274,494 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AI167215 | Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells | 000 | 3 | NIH | 6/28/2024 | $997,966 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AI174357 | Development of ultra-efficient antibodies for single cell mapping applications | 000 | 2 | NIH | 2/19/2024 | $1,006,054 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 001 | 3 | NIH | 1/8/2024 | $184,692 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM148145 | Multiomic genomic mapping with long read sequencing | 001 | 3 | NIH | 8/28/2024 | $1,270,748 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AI179547 | Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins | 000 | 2 | NIH | 6/18/2024 | $1,008,869 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG013071 | Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | 000 | 2 | NIH | 9/9/2024 | $1,024,448 |
| | 2024 | 2024 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AG090112 | Versatile platform for genome-wide R-loop mapping for aging and neurodegenerative disease research | 000 | 1 | NIH | 9/23/2024 | $1,274,632 |
| | 2024 | 2023 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43HG013071 | Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | 000 | 1 | NIH | 9/6/2024 | $0 |
| | 2024 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44AI134162 | Rapid quantification of nuclear citrullination in human neutrophils | 000 | 4 | NIH | 12/21/2023 | $0 |
| | 2024 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM140536 | Single-Cell Chromatin Mapping Assays | 000 | 2 | NIH | 9/23/2024 | $0 |
| | 2024 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 002 | 1 | NIH | 2/1/2024 | $0 |
| | 2024 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM148145 | Multiomic genomic mapping with long read sequencing | 000 | 1 | NIH | 8/6/2024 | $0 |
| | 2024 | 2021 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DE029633 | Development of novel spike-in controls for quantitative chromatin-associated protein profiling | 000 | 3 | NIH | 5/28/2024 | $0 |
| | 2024 | 2021 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK131770 | Development of a high-throughput epigenomic mapping platform to molecularly phenotype Crohn's disease | 000 | 1 | NIH | 7/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $12,622,074 ) |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R43HG013071 | Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | 000 | 1 | NIH | 4/26/2023 | $406,324 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44TR004227 | A molecular toolbox to accelerate drug development for histone lysine methylation regulators | 000 | 2 | NIH | 4/15/2023 | $1,025,085 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R43CA284973 | Epigenomic analysis of cell-free nucleosomes for cancer research | 000 | 1 | NIH | 6/22/2023 | $406,374 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44AI174357 | Development of ultra-efficient antibodies for single cell mapping applications | 000 | 1 | NIH | 3/10/2023 | $1,007,748 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44GM149036 | Novel recombinant sensors to study histone ubiquitin signaling | 000 | 1 | NIH | 5/29/2023 | $1,276,822 |
| | 2023 | 2023 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM148145 | Multiomic genomic mapping with long read sequencing | 000 | 2 | NIH | 8/31/2023 | $1,272,936 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44AI167215 | Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells | 000 | 2 | NIH | 7/28/2023 | $1,022,964 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44GM145007 | Engineered super-affinity reagents for detection of histone post-translational modifications | 000 | 2 | NIH | 12/1/2022 | $1,024,329 |
| | 2023 | 2023 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK131770 | Development of a high-throughput epigenomic mapping platform to molecularly phenotype Crohn's disease | 000 | 3 | NIH | 8/16/2023 | $1,002,068 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44AI162386 | A new epigenetic toolbox for inflammation research and drug discovery | 000 | 3 | NIH | 4/10/2023 | $1,012,272 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 000 | 2 | NIH | 3/27/2023 | $1,035,703 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 001 | 2 | NIH | 7/26/2023 | $96,090 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44AI179547 | Rapid and robust assay for measurement of in vivo activity of chromatin-interacting proteins | 000 | 1 | NIH | 7/19/2023 | $1,008,869 |
| | 2023 | 2023 | EPICYPHER INC | 6 DAVIS DR | DURHAM | NC | 27709 | DURHAM | USA | R44GM131560 | Quantification of combinatorial epigenetic modifications using defined nucleosome standards | 000 | 3 | NIH | 5/19/2023 | $1,024,490 |
| | 2023 | 2021 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43AI165019 | Development of ultra-efficient antibodies for single cell mapping applications | 000 | 1 | NIH | 8/25/2023 | $0 |
| | 2023 | 2021 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG011006 | Quantitative and highly versatile chromatin accessibility platform | 000 | 2 | NIH | 5/4/2023 | $0 |
| | 2023 | 2021 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM136172 | Multiplex nucleosome-based profiling for the development of next-generation chromatin labeling reagents | 000 | 2 | NIH | 9/28/2023 | $0 |
| | 2023 | 2020 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44GM119893 | Novel enzyme inhibitor screening platform using modified designer nucleosomes | 000 | 3 | NIH | 4/6/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $11,888,731 ) (Continued on the next page) |
| | 2022 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG011875 | Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | 000 | 1 | NIH | 1/25/2022 | $426,207 |
| | 2022 | 2022 | EPICYPHER, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44HG010595 | Quantitative mapping of combinatorial histone modifications | 000 | 3 | NIH | 8/4/2022 | $1,024,752 |
|
| Loading… |
|
